Navigation Links
GenVec to Present at the 2011 10th Annual BIO Investor Forum
Date:10/18/2011

GAITHERSBURG, Md., Oct. 18, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a Company overview highlighting recent developments at the 2011 10th Annual BIO Investor Forum on Tuesday, October 25, 2011 at 3:00 p.m. PDT at the Palace Hotel in San Francisco.

A webcast of Dr. Fischer's presentation will be available both live and on replay. The presentation will be available via webcast at http://www.veracast.com/webcasts/bio/investorforum2011/14112492.cfm. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of GenVec's presentation may also be accessed via the investors and media section of the Company's Web site at http://ir.genvec.com under "Events & Presentations."

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission. Retail Investor and Media Contact:Institutional Investor Contact:GenVec, Inc.

S.A. Noonan CommunicationsDouglas J. Swirsky

Susan A. Noonan(240) 632-5510(212) 966-3650dswirsky@genvec.com

susan@sanoonan.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Renews Stockholder Rights Plan
2. GenVec Reports First Quarter 2011 Financial Results
3. GenVec Regains Compliance with NASDAQ Listing Requirements
4. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
5. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
6. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
7. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
8. GenVec Reports Third Quarter 2009 Financial Results
9. GenVec Announces Third Quarter 2009 Results Conference Call
10. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
11. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... NetDimensions announced today that Scandinavian Health Limited ... management for consistent implementation of standards and regulatory requirements across SHL companies worldwide. ... improve and streamline their training and employee development programs, which are critical to ...
(Date:3/28/2017)... ... March 28, 2017 , ... Ecovia ... Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). Under the ... to develop a suite of BioGelâ„¢ biopolymer materials for hygiene applications, particularly for ...
(Date:3/28/2017)... 28, 2017 Volition America, Inc., a wholly-owned U.S. ... engagement of Deborah Vollmer Dahlke , DrPH, CEO and ... Vollmer Dahlke,s role will be to assist the ... State of Texas and elsewhere in ... has significant experience over the past six years, helping ...
(Date:3/28/2017)... -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or ... to treat cancers and other life-threatening conditions of the ... McGorry, CEO of Biostage, will present on the ... MassBio 2017 Annual Meeting on Thursday, March ... The 3D Printing and BioEngineering panel will ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud ... Continue Reading ... Used combined in one project, multi-biometric solutions provide a ... Used combined ... ...
Breaking Biology News(10 mins):